Drug Discovery Services Market to Reach USD 76.5 Billion by 2033 with a CAGR of 14.5%

The global drug discovery services market is poised for remarkable growth, with its valuation projected to surge from US$ 19.7 billion in 2023 to US$ 76.5 billion by 2033, reflecting a compound annual growth rate (CAGR) of 14.5% over the forecast period. This exponential growth is driven by the rising demand for novel drugs to combat a wide range of unmet medical needs.

The continuous emergence of new diseases and the growing prevalence of neurodegenerative, cancer, rare genetic, and cardiovascular diseases have intensified the need for innovative drug discovery solutions. Despite advancements in healthcare, effective treatments for these conditions remain limited, leading to increased investments in drug discovery research and development (R&D). The development of precision medicines and targeted therapies is also spurring market growth.

The shift toward outsourcing drug discovery services is playing a pivotal role in market expansion. Pharmaceutical and biotechnology companies are increasingly relying on external partners to accelerate drug discovery, reduce operational costs, and leverage specialized expertise. This outsourcing trend is fueling demand for advanced technologies like AI-driven drug discovery, high-throughput screening, and computational biology, which are revolutionizing the drug development process.

Request a Sample of this Report Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-14258

With pharmaceutical firms racing to discover treatments for emerging diseases and chronic conditions, the market for drug discovery services is expected to maintain strong momentum. Investments in research collaborations, innovative drug development platforms, and personalized medicine will continue to support sustained market growth throughout the next decade.

Key Takeaways:

The global drug discovery services market is projected to grow from US$ 19.7 billion in 2023 to US$ 76.5 billion by 2033, with a CAGR of 14.5%.
Growing demand for drugs to treat neurodegenerative, cancer, rare genetic, and cardiovascular diseases is driving the market.
The rise in outsourcing drug discovery services is fueling demand for AI-driven screening, high-throughput screening, and computational biology.
Investments in personalized medicine, R&D collaborations, and precision drug development are expected to support sustained market growth.

Market Drivers

Unmet Medical Needs: There is a continuous demand for new drugs to address various unmet medical needs, particularly for diseases such as neurodegenerative disorders, cancer, rare genetic conditions, and cardiovascular diseases.
Emergence of New Diseases: The rise of new diseases is escalating the demand for innovative drug discovery solutions, further driving the market.
Advancements in Drug Discovery Techniques: Innovations in drug discovery methodologies and technologies are enhancing the efficiency and effectiveness of the drug development process.
Increased R&D Expenditure: Pharmaceutical companies are increasing their research and development expenditures to discover novel drugs, contributing to market growth.
Collaboration Between Stakeholders: Enhanced collaborations between pharmaceutical companies, academic institutions, and contract research organizations (CROs) are fostering advancements in drug discovery services.

Which Growth Strategies are Likely to be Adopted by Market Players?

The global drug discovery services market is competitive, with Laboratory Corporation of America Holdings (United States), Charles River Laboratories International Inc. (United States), WuXi AppTec (China), and Thermo Fisher Scientific Inc. (United States) collectively accounting for a large portion of the market. The United States-based company, Laboratory Corporation of America Holdings, is a prominent player in the global market.

These key players in the global drug discovery market focus on a broad spectrum of clients. They emphasize incorporating modern and advanced technology-enabled solutions. Increasing investments in joint ventures & partnerships are likely to be prevalent as key strategies. Extensive quality systems and processes contribute to the growth of businesses operating in the market. These companies may use organic and inorganic growth techniques, such as acquisitions and expansions, to tap into new demographics.

Several drugs are pending approval from the United States Food and Drug Administration (FDA).

Anticipated Drug Approvals in 2023:

In January 2023, Genentech declared that it received a Priority Review and Fast Track designation grant for Glofitamab. The drug is a novel bispecific antibody that engages T-cells of the immune system to treat adult patients with refractory or relapsed LBCL.
In January 2023, Brexpiprazole, an atypical antipsychotic supplement NDA approved for schizophrenia was put under Priority Review by FDA. Brexpiprazole is a drug developed by H. Lundbeck A/S and Otsuka Pharmaceuticals.
In January 2023, UCB's Rozanolixizumab was accepted by the FDA for further Phase III study.
In December 2022, Harm Reduction Therapeutics announced that FDA accepted and granted Priority for Review to their NDA for RiVive. The product is an over-the-counter naloxone nasal spray.

Key Players in the Market

Laboratory Corporation of America Holdings
Charles River Laboratories International Inc.
Genscript Biotech Corporation
Thermo Fisher Scientific Inc.
Pharmaron Beijing Co. Ltd.
Evotec SE
Eurofins Scientific SE
Pharmaceutical Product Development Inc.
Piramal Enterprise Limited
Syngene International Limited

Market Segmentation

By Process:

Target Selection
Target Validation
Hit-to-lead identification
Lead Optimization
Candidate Validation

By Type:

Chemistry Services
Biology Services

By Drug Type:

Small Molecule Drugs
Biologics Drugs

By Therapeutic Area:

Neurology
Infectious and Immune Systems Diseases
Digestive System Diseases
Oncology
Other Therapeutic Areas

By End User:

Pharmaceutical & Biotechnology Companies
Academic Institutes
Manufacturing
Other End Users

By Region:

North America
Latin America
Europe
Asia Pacific
The Middle East & Africa

Explore FMI's Related Ongoing Coverage on Healthcare Market Insights Domain:

Body Contouring Market - https://www.futuremarketinsights.com/reports/body-contouring-market

Pancreatic Stone Protein Testing Market - https://www.futuremarketinsights.com/reports/pancreatic-stone-protein-testing-market

Gastric Space-Occupying Devices Market - https://www.futuremarketinsights.com/reports/gastric-space-occupying-devices-market

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

This release was published on openPR.